Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HUM
stocks logo

HUM

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
31.85B
+7.81%
5.870
-15.66%
31.48B
+7.1%
2.574
-38.13%
31.30B
+7.15%
-3.457
+60.03%
Estimates Revision
The market is revising Upward the revenue expectations for Humana Inc. (HUM) for FY2025, with the revenue forecasts being adjusted by 1.21% over the past three months. During the same period, the stock price has changed by -8.68%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.22%
In Past 3 Month
Stock Price
Go Down
down Image
-8.68%
In Past 3 Month
15 Analyst Rating
up Image0
Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 296.47 USD with a low forecast of 244.00 USD and a high forecast of 348.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
8 Hold
0 Sell
Moderate Buy
up Image0
Current: 241.450
sliders
Low
244.00
Averages
296.47
High
348.00
up Image0
Current: 241.450
sliders
Low
244.00
Averages
296.47
High
348.00
Barclays
Andrew Mok
Equal Weight
downgrade
$273 -> $268
2025-06-12
Reason
Barclays
Andrew Mok
Price Target
$273 -> $268
2025-06-12
downgrade
Equal Weight
Reason
Barclays analyst Andrew Mok lowered the firm's price target on Humana to $268 from $273 and keeps an Equal Weight rating on the shares as part of an investor day preview. The firm expects the company to outline embedded earnings and the path to 3% Medicare Advantage margins, but does not anticipate any formal earnings targets or 2026 guidance.
Barclays
Equal Weight
downgrade
$322 -> $273
2025-06-02
Reason
Barclays
Price Target
$322 -> $273
2025-06-02
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on Humana to $273 from $322 and keeps an Equal Weight rating on the shares. Following Q1 earnings and "several negative data points" around Part D mix, Affordable Care Act trend, and preliminary 2026 ACA rates, the firm is more concerned on the Medicare Part D and individual ACA businesses, which it believes carry negative earnings risk for the balance of 2025 and face significant premium increases and disruption in 2026. With limited prospects of multiple expansion and an unfavorable managed care catalyst calendar, investors are likely to be more sensitive to earnings revisions, which skew negatively for Part D- and ACA-sensitive stocks, the analyst tells investors in a research note. Barclays continues to prefer hospitals to managed care.
Truist
David MacDonald
Hold
downgrade
$325 -> $305
2025-05-12
Reason
Truist
David MacDonald
Price Target
$325 -> $305
2025-05-12
downgrade
Hold
Reason
Truist analyst David MacDonald lowered the firm's price target on Humana to $305 from $325 and keeps a Hold rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Baird
Michael Ha
Hold
Maintains
$270 → $300
2025-04-15
Reason
Baird
Michael Ha
Price Target
$270 → $300
2025-04-15
Maintains
Hold
Reason
Barclays
Andrew Mok
Hold
Maintains
$270 → $322
2025-04-11
Reason
Barclays
Andrew Mok
Price Target
$270 → $322
2025-04-11
Maintains
Hold
Reason
Truist Securities
David Macdonald
Hold
Maintains
$290 → $325
2025-04-11
Reason
Truist Securities
David Macdonald
Price Target
$290 → $325
2025-04-11
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Humana Inc (HUM.N) is 15.08, compared to its 5-year average forward P/E of 19.55. For a more detailed relative valuation and DCF analysis to assess Humana Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
19.55
Current PE
15.08
Overvalued PE
22.96
Undervalued PE
16.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.51
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.59
Undervalued EV/EBITDA
10.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.53
Current PS
0.00
Overvalued PS
0.68
Undervalued PS
0.39

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased100%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

HUM News & Events

Events Timeline

(ET)
2025-06-16
16:31:35
Senate Republicans abandon Medicare cost cuts, Bloomberg reports
select
2025-06-05 (ET)
2025-06-05
14:06:21
Senate Republicans consider Medicare spending cuts, Bloomberg says
select
2025-06-05
06:03:45
Humana to support moves to curb Medicare billing practices, WSJ says
select
link
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
06-17Benzinga
Truist Securities Maintains Hold on Humana, Lowers Price Target to $280

  • Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and real-time intelligence to help traders succeed in the stock market.

  • Exclusive Community Access: Joining Benzinga Pro connects you with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Preview
8.0
06-17NASDAQ.COM
Notable Monday Option Activity: HUM, MPW, WYNN

  • Medical Properties Trust Inc (MPW) Options Activity: MPW options have seen a trading volume of 44,409 contracts today, with significant activity in the $4 strike put option expiring September 19, 2025, totaling 17,538 contracts.

  • Wynn Resorts Ltd (WYNN) Options Activity: WYNN options recorded a volume of 12,209 contracts, particularly high for the $82 strike put option expiring June 20, 2025, with 1,352 contracts traded.

Preview
7.0
06-17SeekingAlpha
Humana doesn't project achieving four-star Medicare Advantage rating until 2028

  • Humana's Medicare Stars Rating Outlook: Humana does not expect to achieve a four-star rating in the Medicare Stars Ratings program until 2028, despite implementing various strategies to improve its performance and accountability.

  • Legal Challenges and Performance Improvements: The company missed the four-star rating for bonus year 2026 due to minor point deficiencies and is currently planning its business around the outcome of a lawsuit against CMS regarding its rating loss.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Humana Inc (HUM) stock price today?

The current price of HUM is 241.45 USD — it has increased 2.57 % in the last trading day.

arrow icon

What is Humana Inc (HUM)'s business?

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.

arrow icon

What is the price predicton of HUM Stock?

Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 296.47 USD with a low forecast of 244.00 USD and a high forecast of 348.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Humana Inc (HUM)'s revenue for the last quarter?

Humana Inc revenue for the last quarter amounts to 32.11B USD, increased 8.45 % YoY.

arrow icon

What is Humana Inc (HUM)'s earnings per share (EPS) for the last quarter?

Humana Inc. EPS for the last quarter amounts to 10.29 USD, increased 68.41 % YoY.

arrow icon

What changes have occurred in the market's expectations for Humana Inc (HUM)'s fundamentals?

The market is revising Upward the revenue expectations for Humana Inc. (HUM) for FY2025, with the revenue forecasts being adjusted by 1.21% over the past three months. During the same period, the stock price has changed by -8.68%.
arrow icon

How many employees does Humana Inc (HUM). have?

Humana Inc (HUM) has 65680 emplpoyees as of June 18 2025.

arrow icon

What is Humana Inc (HUM) market cap?

Today HUM has the market capitalization of 29.14B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free